NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Sep 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
SANCUSO (granisetron) by Cumberland Pharmaceuticals is serotonin 3 receptor antagonists [moa]. Approved for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting. First approved in 2008.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANCUSO is a transdermal extended-release film formulation of granisetron, a selective serotonin 3 receptor antagonist used to prevent nausea and vomiting in adults receiving moderately to highly emetogenic chemotherapy for up to 5 consecutive days. It blocks serotonin signaling at 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone to suppress the vomiting reflex.
$7MPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest commercial scale (~3,200 Part D claims in 2023), signaling transition from growth to maintenance mode and potential consolidation of brand teams.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Worked on SANCUSO at Cumberland Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.